Annexon, Inc. (ANNX)

Over the past six months, Annexon, Inc. (ANNX) stock has shown significant momentum, delivering a 137% return. In Q3 2025, Annexon reported an EPS of -$0.37, missing analysts' expectations, and its net loss widened due to increased R&D expenses. Annexon completed a public offering in November 2025, raising approximately $86.25 million to fund clinical programs and extend its operational runway into late Q1 2027. Annexon has a consensus rating of "Moderate Buy" from Wall Street analysts, with an average twelve-month stock price forecast of $17.00. The anticipated Marketing Authorization Application (MAA) submission in the European Union for tanruprubart (ANX005) in January 2026 is a key regulatory milestone.

As a clinical-stage biopharmaceutical company, Annexon, Inc. does not have commercialized products, so traditional demand seasonality does not apply. Its financial performance is driven by research and development milestones, clinical trial results, and regulatory approvals. Clinical trial timelines or disease prevalence patterns might indirectly influence the company's activities and news flow. The timing of regulatory submissions and clinical trial data announcements, such as the anticipated MAA filing in January 2026 and the ARCHER II Phase 3 readout in the second half of 2026, represent key periods of potential market interest and stock price movement.

Annexon, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for classical complement-mediated disorders. The company targets the C1q molecule to halt neuroinflammation and tissue damage. Its pipeline includes Tanruprubart (ANX005) in Phase 3 for Guillain-Barré Syndrome (GBS), Vonaprument (ANX007) in Phase 3 for geographic atrophy (GA), ANX1502 in Phase 1 for autoimmune indications, and ANX009 in Phase I for lupus nephritis. Tanruprubart is a potential first-in-class therapy for GBS, with a Marketing Authorization Application (MAA) submission in the European Union anticipated in January 2026. Vonaprument is an intravitreal C1q inhibitor with the potential to be the first approved vision-sparing therapy for GA, with topline data from the ARCHER II Phase 3 trial expected in the second half of 2026. ANX1502 is a first-in-kind oral C1s inhibitor.

Annexon, Inc. was established in 2011 and initially operated in South San Francisco, California, before relocating its headquarters to Brisbane, California. While its primary operations are in the United States, Annexon is engaged in regulatory activities in the European Union.

Annexon's brand reputation is tied to its scientific advancements and clinical trial progress in developing therapies for severe neuroinflammatory diseases. Progress of Tanruprubart (ANX005) for GBS and Vonaprument (ANX007) for GA positively impacts its scientific and clinical reputation. A "Moderate Buy" consensus rating from Wall Street analysts and the successful completion of a public offering indicate investor confidence. No specific negative events significantly impacting Annexon's brand reputation in the past year were found.

Annexon, Inc. is predominantly owned by institutional investors, holding approximately 88.46% to 100.05% of the float. As of recent filings, 258 institutional owners hold a total of 114,429,913 shares. Major institutional owners include Fmr Llc, BlackRock, Inc., and Vanguard Group Inc. Individual insider ownership is relatively small, around 1.61% of the shares.